{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:26:54Z","timestamp":1784824014007,"version":"3.55.0"},"reference-count":58,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line setting. Emerging immunochemotherapies have shown activity in small studies of heavily pre-treated patients with prolonged remissions achieved in some patients. Anti-CD19 CAR (chimeric antigen receptor) T cells are potentially curative in the 3rd line and beyond setting and are under investigation in earlier lines of therapy. Antibody-drug conjugates (ADC\u2019s) such as polatuzumab vedotin targeting the pan-B-cell marker CD79b has proven effectiveness in multiply-relapsed DLBCL patients. Tafasitamab (MOR208) is an anti-CD19 monoclonal antibody producing prolonged remissions when combined with Lenalidomide (LEN) in patients who were not candidates for salvage chemotherapy or autologous stem cell transplant. Selinexor, an oral, small-molecule selective inhibitor of XPO1-mediated nuclear export (SINE), demonstrated prolonged activity against heavily-pretreated DLBCL without cumulative toxicity and is being investigated as part of an oral, chemotherapy-free regimen for relapsed aggressive lymphoma. This article reviews current strategies and novel therapies for relapsed\/refractory DLBCL.<\/jats:p>","DOI":"10.3390\/ijms21228553","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T08:44:02Z","timestamp":1605257042000},"page":"8553","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4967-4618","authenticated-orcid":false,"given":"Leonard Jeff","family":"Harris","sequence":"first","affiliation":[{"name":"Oncology Division, Department of Medicine, University of Tennessee Health Sciences Center, Memphis, TN 38103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6527-5916","authenticated-orcid":false,"given":"Kruti","family":"Patel","sequence":"additional","affiliation":[{"name":"Oncology Division, Department of Medicine, University of Tennessee Health Sciences Center, Memphis, TN 38103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Martin","sequence":"additional","affiliation":[{"name":"West Cancer Center &amp; Research Institute, Memphis, TN 38103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1080\/10428194.2020.1734592","article-title":"The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy","volume":"61","author":"Tkacz","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.anndiagpath.2018.09.014","article-title":"Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues","volume":"38","author":"Grimm","year":"2019","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: A prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Schmitz","year":"2016","journal-title":"Bone Marrow Transpl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.hoc.2016.07.004","article-title":"Management of Relapsed Diffuse Large B-cell Lymphoma","volume":"30","author":"Crump","year":"2016","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2217\/cer-2019-0062","article-title":"Second-line rituximab-bendamustine versus rituximab-gemcitabine-oxaliplatin in diffuse large B-cell lymphoma in the real world","volume":"8","author":"Shang","year":"2019","journal-title":"J. Comp. Eff. Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Vosuri, V., Kaisreddy, R., and Bandi, S. (2019). Comparison of salvage therapies for relapsed or refractory diffuse large B-cell lymphoma (DLBCL): Network meta-analysis. J. Clin. Oncol., 37.","DOI":"10.1200\/JCO.2019.37.15_suppl.e19037"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Nabhan, C., Klink, A., Lee, C.H., Laney, J.R., Yang, Y., and Purdum, A.G. (2018). Overall survival (OS) and transplantation (ASCT) utilization in real-world patients with relapsed\/refractory diffuse large B-cell lymphoma (RR-DLBCL). J. Clin. Oncol., 36.","DOI":"10.1200\/JCO.2018.36.15_suppl.7545"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Coyle, L., Morley, N.J., Rambaldi, A., Mason, K.D., Verhoef, G., Furness, C.L., Zhang, A., Jung, A.S., Cohan, D., and Franklin, J.L. (2020). Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma. Leuk. Lymphoma, 1\u201310.","DOI":"10.1182\/blood-2020-141117"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1634\/theoncologist.2018-0490","article-title":"Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies","volume":"24","author":"Purdum","year":"2019","journal-title":"Oncologist"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Patel, K.K., Isufi, I., Kothari, S., Foss, F., and Huntington, S. (2020). Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leuk. Lymphoma, 1\u20138.","DOI":"10.1080\/10428194.2020.1808208"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): A single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1182\/blood-2019-124297","article-title":"A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin\u2019s Lymphoma: Long-Term Follow-up, Final Analysis","volume":"134","author":"Jurczak","year":"2019","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Nowakowski, G.S., Rodgers, T.D., Marino, D., Frezzato, M., Barbui, A.M., Castellino, C., Meli, E., Fowler, N.H., Feinberg, B.A., and Tillmann, S. (2020). RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL). J. Clin. Oncol., 38.","DOI":"10.1200\/JCO.2020.38.15_suppl.8020"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2013.95","article-title":"Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: A phase II clinical trial","volume":"27","author":"Wang","year":"2013","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1158\/2159-8290.CD-RW2020-091","article-title":"Diffuse Large B-cell Lymphoma Responds to Tafasitamab plus Lenalidomide","volume":"10","author":"Rose","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lu, T., Gibiansky, L., Li, X., Li, C., Shi, R., Agarwal, P., Hirata, J., Miles, D., Chanu, P., and Girish, S. (2020). Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma. Leuk. Lymphoma, 1\u201310.","DOI":"10.1080\/10428194.2020.1795154"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"OF2","DOI":"10.1158\/2159-8290.CD-NB2019-076","article-title":"Polatuzumab Vedotin Approved for DLBCL","volume":"9","author":"Shingleton","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_30","unstructured":"(2020, August 14). Polavy FDA Prescriber Label, Available Online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761121s000lbl.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Haioun, C., Matasar, M.J., Sancho, J.-M., Viardot, A., Hernandez, J., Perretti, T., and McMillan, A. (2020). POLARGO: Randomized Phase III study of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL). J. Clin. Oncol., 38.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8070"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMsa0803563","article-title":"Rehospitalizations among Patients in the Medicare Fee-for-Service Program","volume":"360","author":"Jencks","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e500","DOI":"10.1016\/S2352-3026(20)30178-2","article-title":"Selective inhibitors of nuclear export in aggressive B-cell lymphomas","volume":"7","author":"Chiappella","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Osborne, W., Marzolini, M., Tholouli, E., Ramakrishnan, A., Bachier, C.R., McSweeney, P.A., Irvine, D., Zhang, M., Al-Hajj, M.A., and Pule, M. (2020). Phase I Alexander study of AUTO3, the first CD19\/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed\/refractory (r\/r) DLBCL. J. Clin. Oncol., 38.","DOI":"10.1200\/JCO.2020.38.15_suppl.8001"},{"key":"ref_35","first-page":"2040620719841581","article-title":"CAR T-cell therapy for B-cell lymphomas: Clinical trial results of available products","volume":"10","author":"Chavez","year":"2019","journal-title":"Adv. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Fitzgerald, L., Kittai, A., Nastoupil, L.J., Waller, A., Jacobson, C.A., Saucier, A., Kamdar, M.K., Spradley, J., Denlinger, N., and Chipman, J. (2020). Real-world outcomes of elderly patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy. J. Clin. Oncol., 38.","DOI":"10.1200\/JCO.2020.38.15_suppl.8039"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Roex, G., Feys, T., Beguin, Y., Kerre, T., Poire, X., Lewalle, P., Vandenberghe, P., Bron, D., and Anguille, S. (2020). Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12020194"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1200\/EDBK_279043","article-title":"ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma","volume":"40","author":"Abramson","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Hutchings, M., Lugtenburg, P., Mous, R., Clausen, M.R., Chamuleau, M., Linton, K., Rule, S., Lopez, J.S., Oliveri, R.S., and DeMarco, D. (2020). Epcoritamab (GEN3013; DuoBody-CD3\u00d7CD20) to induce complete response in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I\/II trial. J. Clin. Oncol., 38.","DOI":"10.1200\/JCO.2020.38.15_suppl.8009"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1182\/blood-2019-122451","article-title":"Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed\/Refractory (R\/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)","volume":"134","author":"Bannerji","year":"2019","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood-2019-123949","article-title":"Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial","volume":"134","author":"Morschhauser","year":"2019","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Maddocks, K.J., Duell, J., Barca, E.G., Jurczak, W., Liberati, A.M., Nagy, Z., Obr, A., Gaidano, G., Andr\u00e9, M., and Kalakonda, N. (2019). Update of the single-arm phase II L-MIND study of MOR208 + lenalidomide (LEN) in relapsed\/refractory diffuse large B-cell lymphoma (R-R DLBCL): Response rates in patient subgroups with poor prognosis. J. Clin. Oncol., 37.","DOI":"10.1200\/JCO.2019.37.15_suppl.7521"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Advani, R.H., Flinn, I., Popplewell, L., Forero-Torres, A., Bartlett, N.L., Ghosh, N., Kline, J.P., Tran, T., Lynn, J., and Chen, J.Y. (2018). Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed\/refractory non-Hodgkin lymphoma: Initial phase 1b\/2 results. J. Clin. Oncol., 36.","DOI":"10.1200\/JCO.2018.36.15_suppl.7504"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Herbaux, C., Casasnovas, O., Feugier, P., Damaj, G., Bouabdallah, R., Guidez, S., Ysebaert, L., Tilly, H., Gouill, S.L., and Fornecker, L. (2020). Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R\/R DLBCL): Primary analysis of a phase II trial from LYSA. J. Clin. Oncol., 38.","DOI":"10.1200\/JCO.2020.38.15_suppl.8053"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Chen, R.W., Ansell, S.M., Zinzani, P.L., Vacirca, J.L., Lopez-Guillermo, A., Hutchings, M., Jurczak, W., Hess, G., Gouill, S.L., and Offner, F. (2017). Phase 1b\/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R\/R DLBCL). J. Clin. Oncol., 35.","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS7575"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Shah, N.N., Zhu, F., Schneider, D., Taylor, C., Krueger, W., Worden, A., Longo, W.L., Hamadani, M., Fenske, T., and Johnson, B. (2019). Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma. J. Clin. Oncol., 37.","DOI":"10.1200\/JCO.2019.37.15_suppl.2510"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7580","DOI":"10.1200\/JCO.2018.36.15_suppl.7580","article-title":"Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study","volume":"36","author":"Fanale","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Duque, A.E.D., Perekhrestenko, T., Musteata, V., Zodelava, M., Guthrie, T.H., Strack, T., Burnett, C., Wilson, S., Waltzman, R.J., and Baetz, T.D. (2020). A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol., 38.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8074"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e19038","DOI":"10.1200\/JCO.2019.37.15_suppl.e19038","article-title":"Phase 2 study of parsaclisib (INCB050465) for relapsed or refractory diffuse large b-cell lymphoma (DLBCL) (CITADEL-202)","volume":"37","author":"Coleman","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Coleman, M., Forero-Torres, A., Ribrag, V., Chau, I., DeMarini, D.J., and Zinzani, P.L. (2017). Phase 2 study of the safety and efficacy of INCB050465 in patients with relapsed or refractory (R\/R) diffuse large b-cell lymphoma (DLBCL) (CITADEL-202). J. Clin. Oncol., 35.","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS7579"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Batlevi, C.L., Frank, S.D., Stewart, C., Hamlin, P.A., Matasar, M.J., Gerecitano, J.F., Moskowitz, A.J., Hamilton, A.M., Zelenetz, A.D., and Drullinsky, P. (2018). Phase I\/II clinical trial of ibrutinib and buparlisib in relapsed\/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. J. Clin. Oncol., 36.","DOI":"10.1200\/JCO.2018.36.15_suppl.7520"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Yang, H., Xiang, B., Song, Y., Zhang, H., Zhao, W., Zou, D., Lv, F., Bai, O., Liu, A., and Li, C. (2020). Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: Results from a phase II, single-arm, multicenter, study. J. Clin. Oncol., 38.","DOI":"10.1200\/JCO.2020.38.15_suppl.e20051"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"de la Merino, L.C. (2020). Lenalidomide plus R-GDP (R2-GDP) in relapsed\/refractory diffuse large B-cell lymphoma: Final results of the R2-GDP-GOTEL trial. J. Clin. Oncol., 38.","DOI":"10.1200\/JCO.2020.38.15_suppl.8019"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Guerra-Bauman, F., LaPlant, B., Macon, W.R., Witzig, T.E., Farooq, U., Nowakowski, G.S., and Feldman, T. (2020). Phase I\/II study of R-ICE (rituximab-ifosfamide-carboplatin-etoposide) with lenalidomide (R2-ICE) in patients with first-relapse\/primary refractory diffuse large B-cell lymphoma (DLBCL) in academic and community cancer research united (ACCRU) network. J. Clin. Oncol., 38.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8073"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/22\/8553\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:32:53Z","timestamp":1760178773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/22\/8553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,13]]},"references-count":58,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["ijms21228553"],"URL":"https:\/\/doi.org\/10.3390\/ijms21228553","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202009.0718.v1","asserted-by":"object"}]},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,13]]}}}